Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has appointed Lisa Wyman as the Chief Technical and Quality Officer (CTQO) to support the company's growth and evolution. Wyman brings with her more than 20 years of leadership and functional experience in technical and quality operations, having previously held executive roles at Generate:Biomedicines and Acceleron Pharma.
As a part of the organizational restructuring, the role of Chief Operating Officer (COO) at Scholar Rock is being eliminated, and the company is in search of a new Chief Financial Officer (CFO). Ted Myles, the current COO & CFO, will continue with the company through mid-March and then serve as a senior advisor for six months during the leadership transition.
The company is preparing for its first expected drug approval and commercial launch in 2025, with Wyman's appointment seen as fortifying the company's readiness to bring apitegromab to the market for patients and expanding technical and quality operations for the earlier stage clinical pipeline.
Wyman's previous experience includes serving as the Chief Technical Operations Officer at Generate:Biomedicines, where she was responsible for establishing and building out the global technical operations organization. She also held senior roles at Acceleron, Mersana Therapeutics, Shire, and Boston Scientific.
Scholar Rock is focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role. The company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions. The market has reacted to these announcements by moving the company's shares 0.3% to a price of $42.46. If you want to know more, read the company's complete 8-K report here.
